• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form RW filed by Neovasc Inc.

    4/11/23 9:11:04 AM ET
    $NVCN
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $NVCN alert in real time by email
    RW 1 tm239185d3_rw.htm RW

     

    April 11, 2023

     

    VIA EDGAR

     

    Securities and Exchange Commission (the “Commission”)
    100 F Street, N.E
    Washington, D.C. 20549
    United States of America
    Attention:
    Mr. Joshua Gorsky

     

    RE:Neovasc Inc.
    Request to Withdraw Registration Statement on Form F-3 (File No. 333-264444)

     

    Dear Mr. Joshua Gorsky:

     

    Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), Neovasc Inc. (the “Company”) hereby requests that the above-referenced registration statement on Form F-3 originally filed on April 22, 2022, including all exhibits filed therewith and the amendment thereto (the “Registration Statement”), be withdrawn, effective as of the date hereof.

     

    The Company has determined not to proceed at this time with the registration of the securities proposed to be covered by the Registration Statement. The Registration Statement has not been declared effective and no Company securities have been issued, offered or sold pursuant to the Registration Statement. The Company is withdrawing the Registration Statement on grounds that the withdrawal of the Registration Statement is consistent with the public interest and protection of investors, as contemplated by paragraph (a) of Rule 477 of the Securities Act.

     

    The Company further requests that, in accordance with Rule 457(p) under the Securities Act, all fees paid to the Commission in connection with the filing of the Registration Statements be credited to the Company’s account to be offset against the filing fee for future use by the Company or an affiliate of the Company.

     

    Pursuant to the requirements of Rule 477 under the Securities Act, the Company has duly caused this request for withdrawal to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Very truly yours,

     

    Neovasc Inc.

     

    By: /s/ Chris Clark  
    Name: Chris Clark  
    Title: Chief Financial Officer  

     

    cc:   Michael J. Hong, Esq., Partner, Skadden, Arps, Slate, Meagher & Flom LLP

     

     

     

    Get the next $NVCN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVCN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVCN
    SEC Filings

    See more
    • SEC Form EFFECT filed by Neovasc Inc.

      EFFECT - NEOVASC INC (0001399708) (Filer)

      8/3/23 12:15:07 AM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 15F-12B filed by Neovasc Inc.

      15F-12B - NEOVASC INC (0001399708) (Filer)

      4/24/23 4:15:05 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 6-K filed by Neovasc Inc.

      6-K - NEOVASC INC (0001399708) (Filer)

      4/12/23 1:10:18 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care

    $NVCN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Volato Announces Changes to Board Composition

      Volato to Announce First Quarter 2024 Results on Wednesday, May 15, 2024 Volato Group, Inc. ("Volato," or the "Company") (NYSE:SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company's Board of Directors. As part of this announcement, Joan Sullivan Garrett, Katherine Arris-Wilson, Peter Mirabello, and Dana H. Born have stepped down from the Company's Board of Directors without disagreement. The company is decreasing the size of its board from seven to five members, three of whom are Independent Directors. Fred Colen will serve as an independent director and Chair of the Audit Committee and has been designated as a financial expert. Chris Burger

      4/24/24 6:00:00 AM ET
      $BSX
      $SOAR
      $NVCN
      Medical/Dental Instruments
      Health Care
      Transportation Services
      Consumer Discretionary
    • Neovasc Shareholders Approve Acquisition by Shockwave Medical

      Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ:NVCN) (TSX:NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting").The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareholders o

      3/6/23 6:00:00 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • Neovasc Shareholders Approve Acquisition by Shockwave Medical

      VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareh

      3/6/23 5:37:44 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care

    $NVCN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SVB Leerink resumed coverage on Neovasc with a new price target

      SVB Leerink resumed coverage of Neovasc with a rating of Buy and set a new price target of $2.00

      3/14/21 8:09:11 AM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care

    $NVCN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Neovasc Inc. (Amendment)

      SC 13G/A - NEOVASC INC (0001399708) (Subject)

      2/14/22 3:25:50 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13D filed

      SC 13D - NEOVASC INC (0001399708) (Subject)

      2/25/21 3:14:38 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13G filed

      SC 13G - NEOVASC INC (0001399708) (Subject)

      2/19/21 4:24:07 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care

    $NVCN
    Financials

    Live finance-specific insights

    See more
    • Volato Announces Changes to Board Composition

      Volato to Announce First Quarter 2024 Results on Wednesday, May 15, 2024 Volato Group, Inc. ("Volato," or the "Company") (NYSE:SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company's Board of Directors. As part of this announcement, Joan Sullivan Garrett, Katherine Arris-Wilson, Peter Mirabello, and Dana H. Born have stepped down from the Company's Board of Directors without disagreement. The company is decreasing the size of its board from seven to five members, three of whom are Independent Directors. Fred Colen will serve as an independent director and Chair of the Audit Committee and has been designated as a financial expert. Chris Burger

      4/24/24 6:00:00 AM ET
      $BSX
      $SOAR
      $NVCN
      Medical/Dental Instruments
      Health Care
      Transportation Services
      Consumer Discretionary
    • Neovasc Announces Third Quarter Financial Results and Provides Corporate Update

      VANCOUVER and MINNEAPOLIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") ((NASDAQ, TSX:NVCN) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Generated revenues of $923,000, a quarterly record and a year-over-year increase of 31% compared to the third quarter of 2021. Accelerating acceptance of Reducer in the UK and French markets, with France the largest volume market in the quarter. Continued enrollment in the COSIRA II pivotal trial, with enrollment expected to be complete in the first half of 2024 and initial data readout in the second half of 2024. In July, 2022, the Company re

      11/10/22 4:05:00 PM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care
    • Neovasc to Report Third Quarter Financial Results on November 10, 2022

      VANCOUVER and MINNEAPOLIS, Oct. 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (NASDAQ ,  TSX : NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm ET on November 10, 2022. Interested parties may access the conference call by dialing (800) 458-4121 or (856) 344-9290 (International) and reference Conference ID 7304031. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc we

      10/27/22 9:00:00 AM ET
      $NVCN
      Pharmaceuticals and Biotechnology
      Health Care